Meanwhile, the c-MET ligand HGF can also mediate resistance of NSCLC to gefitinib through the activation of the PI3K/AKT signaling pathway via GAB1 (Grb2 associated binder 1) (61). Here, HGF is linked to non-small cell lung carcinoma.